Public IDs

No public external ID is attached.

Related people

No reviewed person affiliation is attached.

Outputs

No reviewed output is linked through affiliated people.

Topics

Protein and Drug DesignSourceInternational Journal of Newgen Research in Pharmacy & Healthcare SourceClinicalTrials.gov

Relationship evidence

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) (NCT05482893)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Timeline

No dated relationship evidence is attached.